During global health outreach, this involves identifying and miti

During global health outreach, this involves identifying and mitigating the potential

for harm, as well as understanding and respecting cultural differences. Furthermore, pharmacists selleck chemicals llc have an ethical obligation to not only meet individual patient needs, but also community and societal needs, when applicable. In global health outreach, this involves tailoring interventions to the needs of the population served. Because of their unique skillset, pharmacists have the potential to make significant contributions to global health. Applying ethical principles, such as providing the best possible care, respecting cultural differences and meeting societal needs, provides the foundation for successful global health outreach by pharmacists. “
“Chronic

kidney disease (CKD) and anemia are common in patients with heart failure (HF) – these 3 conditions have been coined the Cardiorenal Anemia Sydrome (CRAS). The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines do not specifically address patients with CRAS, creating uncertainty in erythropoietin (EPO) prescribing. We sought to selleck chemicals determine predictors of EPO use in patients with CRAS. We conducted a retrospective cohort study at the Veteran’s Affairs Greater Los Angeles Healthcare System (VAGLAHS), a 300+ bed facility that provides primary and tertiary inpatient, and ambulatory care services, between January 1, 2003 to December 31, 2006. A multiple logistic regression model was constructed to identify predictors of EPO use among CRAS patients. Of 2058 patients with CRAS, 213 (10.3%) were prescribed EPO. There were significant differences Carnitine palmitoyltransferase II in baseline characteristics between the EPO and non-EPO groups. The following predictors were found to be associated with EPO prescription: iron supplementation (odds ratio [OR]

52.70, 95% confidence interval [CI] 11.70–237.46), renal clinic appointment (OR 2.60, 95% CI 1.79–3.76), malignancy (OR 1.52, 95% CI 1.07–2.16) and use of hydralazine/nitrates (OR 1.41, 95% CI 1.03–1.92). There was an inverse association found between EPO prescription and baseline hemoglobin (OR 0.61, 95% CI 0.53–0.70) and eGFR (OR 0.96, 95% CI 0.94–0.97). A small proportion of patients eligible for EPO therapy according to guidelines at the time of the study were prescribed the indicated therapy. Markers of declining renal function or those suggesting need for anemia therapy were identified as EPO predictors. “
“Objective  To obtain pharmacists’ views on proposals for electronic transmission of dispensing data to the New Zealand Intensive Medicines Monitoring Programme (IMMP). Methods  Consultation with a randomly selected group of 100 community pharmacists and all 28 hospital pharmacies in New Zealand was conducted by postal survey.

Comments are closed.